2022
Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells.
McBrearty N, Cho C, Chen J, Zahedi F, Peck A, Radaelli E, Assenmacher C, Pavlak C, Devine A, Yu P, Lu Z, Zhang H, Li J, Pitarresi J, Astsaturov I, Cukierman E, Rustgi A, Stanger B, Rui H, Fuchs S. Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells. Molecular Cancer Research 2022, 21: 228-239. PMID: 36378658, PMCID: PMC9992122, DOI: 10.1158/1541-7786.mcr-22-0602.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancer cellsPDAC cellsCH25H expressionTumor growthT cell tumor infiltrationMouse PDAC cellsImmune checkpoint inhibitorsCancer cellsDownregulation of MHCPancreatic intraepithelial neoplasiaImmune-competent hostsHuman pancreatic cancerPotential translational importanceAccumulation of cholesterolCheckpoint inhibitorsIntraepithelial neoplasiaPoor prognosisTumor infiltrationPancreatic cancerDuctal adenocarcinomaTherapeutic approachesCH25HTumor progressionCholesterol deficit
2020
Fibronectin in the Tumor Microenvironment Activates a TLR4-dependent Inflammatory Response in Lung Cancer Cells
Cho C, Horzempa C, Longo CM, Peters DM, Jones DM, McKeown-Longo PJ. Fibronectin in the Tumor Microenvironment Activates a TLR4-dependent Inflammatory Response in Lung Cancer Cells. Journal Of Cancer 2020, 11: 3099-3105. PMID: 32231714, PMCID: PMC7097952, DOI: 10.7150/jca.39771.Peer-Reviewed Original ResearchType III domainExtracellular matrixLung cancer cellsFibronectin type III domainTumor-associated extracellular matrixCancer cellsFibronectin-rich extracellular matrixTLR4-dependent inflammatory responsesRich extracellular matrixFirst Type III domainIL-8Secondary structureStrained conformationMatrix fibronectinNF-κB pathwayEssential roleFibrotic microenvironmentTumor metastasisPathwayConformational labilityStromal cellsTumor progressionCytokine releaseLung cancerInflammatory response
2016
The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells
Cho C, Horzempa C, Jones D, McKeown-Longo PJ. The fibronectin III-1 domain activates a PI3-Kinase/Akt signaling pathway leading to αvβ5 integrin activation and TRAIL resistance in human lung cancer cells. BMC Cancer 2016, 16: 574. PMID: 27484721, PMCID: PMC4970220, DOI: 10.1186/s12885-016-2621-6.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungCaspase 8Cell Line, TumorCell SurvivalDrug Resistance, NeoplasmFibronectin Type III DomainFibronectinsGene Expression Regulation, NeoplasticHumansLung NeoplasmsPhosphatidylinositol 3-KinasesProtein FoldingProto-Oncogene Proteins c-aktReceptors, VitronectinSignal TransductionTNF-Related Apoptosis-Inducing LigandVitronectinConceptsType III domainLung cancer cellsUnfolded domainsTRAIL resistancePI3-kinase/AktSerine/threonine kinase pathwaysCancer cellsMulti-modular proteinThreonine kinase pathwaysNCI-H460 lung cancer cellsFnIII-1cFirst Type III domainNon-small cell lung cancer cellsTRAIL-induced apoptosisΑvβ5 integrin receptorLung cancer resistanceCell lung cancer cellsHuman lung cancer cellsKinase pathwayCancer cell resistanceIntegrin activationCaspase-8Signaling pathwaysFibronectin matrixSensitive proteinsThe Fibronectin III‐1 Domain Activates a PI3‐Kinase/Akt Signaling Pathway Leading to αvβ5 Integrin Activation and TRAIL Resistance in Human Lung Cancer Cells
Cho C, McKeown‐Longo P. The Fibronectin III‐1 Domain Activates a PI3‐Kinase/Akt Signaling Pathway Leading to αvβ5 Integrin Activation and TRAIL Resistance in Human Lung Cancer Cells. The FASEB Journal 2016, 30: lb82-lb82. DOI: 10.1096/fasebj.30.1_supplement.lb82.Peer-Reviewed Original ResearchLung cancer cellsTRAIL resistanceNon-small cell lung cancerH460 lung cancer cellsCancer cellsCell lung cancerHuman lung cancer cellsLung cancer resistancePI3K/Akt pathwayTumor-stroma interfaceCancer cell resistanceAkt Signaling PathwayΑvβ5 integrin receptorLung cancerImmunohistochemical stainingTumor stromaFirst Type III domainFnIII-1cDrug resistanceBlood vesselsAkt pathwayCancer resistanceSignaling pathwaysFibronectin contributesSubsequent apoptosis